Manufacturing
-
The Future of Tissue-Based Therapies
7/8/2021
Enzyvant's CEO, Rachelle Jacques, explains the company's lead asset, the roadmap for tissue-based therapies, and more.
-
State-of-the-Art GMP Manufacturing RNA Cell Therapies With Cartesian's CEO
8/19/2021
Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector's advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.
-
The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier
2/13/2023
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Andy Ramelmeier, EVP Head of Technical Operations at Sangamo Therapeutics, a biotech based in Brisbane, California that applies cell and gene therapy to combat Hemophilia A and other genetic diseases. Ramelmeier explains the why behind the company's decision to build its own Phase 1/2 cGMP AAV in-house facility. He also talks broadly about manufacturing cell and gene therapies and the potential and realistic solutions to needed to drive down manufacturing costs.
-
Cell Therapy's Current Manufacturing Challenges
4/15/2025
In this segment, Cell & Gene’s Chief Editor, Erin Harris, welcomes the audience and introduces the expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio.
-
4 Keys To Allo In 2024 With Poseida Therapeutics' Kristin Yarema, Ph.D.
1/2/2024
Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin shares how 2024 might see some real progress in allogeneic therapies.
-
Building Patient-Driven Culture and Leadership Resilience in CGT with Paul Perreault
12/2/2025
On episode 117, Host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic.
-
In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
9/26/2023
Discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics, recent progress in lentiviral vector manufacturing, and The Colorado Laboratory and Innovation Manufacturing Building.
-
An Interview With Dr. Carl June
8/9/2022
Dr. Carl June, an HIV gene therapy pioneer and the father of CAR-T cell therapy, joins Cell & Gene: The Podcast to discuss the current state of CAR-T therapy, what's on the short-term horizon for immunotherapy, ongoing manufacturing capacity issues, an update on Emily Whitehead, the first child to receive CAR-T cell therapy on an experimental basis, and more.
-
Inside The World's First-Ever Allogeneic Approval With Atara Biotherapeutics' Pascal Touchon
3/30/2023
In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touchon, talks to Cell & Gene: The Podcast's Erin Harris about the biopharma's path to regulatory approval, commercialization plans for Ebvallo, an in-depth look at EBV+ PTLD, the connection between EBV and serious diseases like multiple sclerosis (MS), and much more.
-
TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou
5/10/2023
Parviz Shamlou, Vice President and Executive Director at Thomas Jefferson University joins Cell & Gene: The Podcast to talk to Host Erin Harris about Jefferson Institute for Bioprocessing (JIB), the full-service development and training organization specializing in biopharmaceuticals and biologics. Shamlou explains how JIB will move forward cell and gene therapies as well as JIB’s partnership with NIBRT (National Institute for Bioprocessing Research & Training), and much more.